---
layout: default
title: Alendronic Acid As Sodium Trihydrate
parent: 僅模型預測 (L5)
nav_order: 34
evidence_level: L5
indication_count: 0
---

# Alendronic Acid As Sodium Trihydrate
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Alendronic Acid: Evaluation Incomplete — No TxGNN Predictions Available

## One-Sentence Summary

Alendronic acid (as sodium trihydrate) is a bisphosphonate compound; however, the current Evidence Pack contains **no TxGNN repurposing predictions**, no original indication data, and no safety information.
A complete drug repurposing evaluation cannot be generated from this dataset in its current state.
Before this candidate can be assessed, several critical data gaps must be resolved.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available in this Evidence Pack |
| Predicted New Indication | No predictions available |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — model prediction stage not yet reached |
| Taiwan Market Status | Not marketed (0 authorizations on record) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why This Prediction Cannot Yet Be Assessed

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on publicly known pharmacological classification, alendronic acid belongs to the **bisphosphonate** drug class, which acts by inhibiting osteoclast-mediated bone resorption — the biological basis for its established use in osteoporosis and Paget's disease of bone.

However, because the `predicted_indications` field in this Evidence Pack is empty, there is no TxGNN repurposing hypothesis to evaluate. Without a predicted new indication, it is not possible to assess mechanism overlap, review supporting clinical trial evidence, or determine whether the drug's known activity translates to a new disease area.

Additionally, no original approved indications are recorded in the Taiwan regulatory dataset, preventing cross-validation against the drug's known therapeutic profile.

---

## Safety Considerations

Please refer to the SmPC for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This Evidence Pack contains no TxGNN repurposing predictions and is missing all critical evaluation inputs — original indications, mechanism of action, safety warnings, and contraindication data. There is no actionable hypothesis to evaluate at this time.

**To proceed, the following is needed:**
- **TxGNN prediction results** for alendronic acid — the pipeline must complete successfully before any repurposing claim can be made
- **Original approved indications** — source from the Taiwan TFDA drug license database or EMA SmPC to populate `original_indications`
- **Mechanism of action** — query the DrugBank API using the INN "alendronic acid" to resolve DG002
- **Safety data** — download and parse the TFDA product information PDF to resolve DG001 (blocking severity)
- **DrugBank ID** — the `drugbank_id` field is null; confirm mapping to `DB00630` (alendronate) before re-running predictions
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

